Oak Associates’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.3M | Sell |
8,192
-1,640
| -17% | -$861K | 0.28% | 52 |
|
|
2025
Q1 | $6.24M | Hold |
9,832
| – | – | 0.47% | 44 |
|
|
2024
Q4 | $7M | Sell |
9,832
-55
| -0.6% | -$39.2K | 0.48% | 45 |
|
|
2024
Q3 | $10.4M | Buy |
9,887
+61
| +0.6% | +$64.1K | 0.7% | 37 |
|
|
2024
Q2 | $10.3M | Hold |
9,826
| – | – | 0.69% | 35 |
|
|
2024
Q1 | $9.46M | Hold |
9,826
| – | – | 0.66% | 40 |
|
|
2023
Q4 | $8.63M | Hold |
9,826
| – | – | 0.65% | 40 |
|
|
2023
Q3 | $8.09M | Buy |
9,826
+35
| +0.4% | +$28.8K | 0.67% | 39 |
|
|
2023
Q2 | $7.04M | Sell |
9,791
-2
| -0% | -$1.44K | 0.56% | 42 |
|
|
2023
Q1 | $8.05M | Hold |
9,793
| – | – | 0.66% | 41 |
|
|
2022
Q4 | $7.07M | Buy |
9,793
+5,881
| +150% | +$4.24M | 0.59% | 44 |
|
|
2022
Q3 | $2.7M | Hold |
3,912
| – | – | 0.23% | 63 |
|
|
2022
Q2 | $2.31M | Buy |
3,912
+337
| +9% | +$199K | 0.18% | 66 |
|
|
2022
Q1 | $2.5M | Hold |
3,575
| – | – | 0.15% | 72 |
|
|
2021
Q4 | $2.26M | Hold |
3,575
| – | – | 0.12% | 80 |
|
|
2021
Q3 | $2.16M | Hold |
3,575
| – | – | 0.12% | 77 |
|
|
2021
Q2 | $2M | Hold |
3,575
| – | – | 0.11% | 80 |
|
|
2021
Q1 | $1.69M | Buy |
3,575
+380
| +12% | +$180K | 0.1% | 86 |
|
|
2020
Q4 | $1.54M | Buy |
3,195
+195
| +7% | +$94.2K | 0.09% | 90 |
|
|
2020
Q3 | $1.68M | Buy |
3,000
+1,615
| +117% | +$904K | 0.11% | 78 |
|
|
2020
Q2 | $864K | Buy |
+1,385
| New | +$864K | 0.06% | 98 |
|